Compare ENGN & MED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ENGN | MED |
|---|---|---|
| Founded | 1999 | 1980 |
| Country | Canada | United States |
| Employees | 82 | N/A |
| Industry | | Packaged Foods |
| Sector | | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.2M | 122.8M |
| IPO Year | N/A | 1996 |
| Metric | ENGN | MED |
|---|---|---|
| Price | $1.84 | $10.15 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 1 |
| Target Price | ★ $21.08 | $12.00 |
| AVG Volume (30 Days) | ★ 1.1M | 280.9K |
| Earning Date | 06-11-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $934,842,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.40 | $9.22 |
| 52 Week High | $12.25 | $15.37 |
| Indicator | ENGN | MED |
|---|---|---|
| Relative Strength Index (RSI) | 42.65 | 33.44 |
| Support Level | $1.68 | $10.01 |
| Resistance Level | $1.96 | $10.30 |
| Average True Range (ATR) | 0.09 | 0.35 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 50.00 | 3.70 |
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. The company provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. The company is focused on offering talent to Lifelong Transformation, Making a Healthy Lifestyle Second Nature.